RT Journal Article
SR Electronic
T1 Role of human challenge trials (HCTs) in drug development for respiratory syncytial virus (RSV)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.05.24.24307680
DO 10.1101/2024.05.24.24307680
A1 Kundu, Prosenjit
A1 Quinn, Mark
A1 Christensen, Jared C.
A1 Thomas, Elaine
A1 Toussi, Sima S.
A1 Alami, Negar Niki
A1 Banerjee, Anindita
YR 2024
UL http://medrxiv.org/content/early/2024/05/24/2024.05.24.24307680.abstract
AB Human challenge trials (HCTs) are powerful in establishing early proof-of-concept for experimental drugs and understanding disease pathogenesis. In this study, we conducted a comprehensive assessment of HCTs to understand the viral load dynamics and symptom score kinetics of respiratory syncytial virus (RSV) to facilitate drug development for RSV. We estimated viral load (VL) and symptom related measures in placebo and relative reduction (RR) of the measures in the experimental drug using a systematic search on double-blind, placebo-controlled RSV HCTs from clinical databases. We used random-effects meta-analysis, except for time to mean peak VL and time to mean peak total symptom score (TSS), where descriptive statistics were summarized. Number of studies varied across measures, from 4 (151 subjects in total) to 7 (247 subjects in total). Overall, treatment reductions of 54% (95% CI: 32% – 76%, I2 = 91%) and 76% (95% CI: 68% – 85%, I2 = 19%) are observed in mean VL area under curve (AUC) and mean TSS AUC, respectively. In placebo, mean time to mean peak VL/TSS was 6.99/7.09 days (95% CI: 6.24/6.06 – 7.74/8.12 days). In comparison to other viruses in HCTs, peak VL occurs earlier for influenza (1.7 days) and at similar time for SARS-nCoV-2 (7 days), whereas peak TSS occurs earlier for influenza (2.9 days) and later for SARS-nCoV-2 (7.9 days). Our findings will inform researchers on disease course and VL kinetics, critical data needed for designing RSV treatment studies and understanding implications in clinical practice.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript.